Barnett S. Kramer

16.2k total citations · 3 hit papers
114 papers, 7.9k citations indexed

About

Barnett S. Kramer is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Barnett S. Kramer has authored 114 papers receiving a total of 7.9k indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Oncology, 37 papers in Pulmonary and Respiratory Medicine and 16 papers in Molecular Biology. Recurrent topics in Barnett S. Kramer's work include Colorectal Cancer Screening and Detection (25 papers), Global Cancer Incidence and Screening (21 papers) and Prostate Cancer Diagnosis and Treatment (19 papers). Barnett S. Kramer is often cited by papers focused on Colorectal Cancer Screening and Detection (25 papers), Global Cancer Incidence and Screening (21 papers) and Prostate Cancer Diagnosis and Treatment (19 papers). Barnett S. Kramer collaborates with scholars based in United States, Malaysia and Denmark. Barnett S. Kramer's co-authors include Philip C. Prorok, Stuart G. Baker, H. Gilbert Welch, Adrian M. Di Bisceglie, Gregory J. Gores, Riccardo Lencioni, Myron Schwartz, Andrew X. Zhu, Jordi Bruix and Jayant A. Talwalkar and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Barnett S. Kramer

112 papers receiving 7.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma

2008 1.3k citations Barnett S. Kramer et al. profile →
The National Lung Screening Trial: Overview and Study Design

2010 899 citations Denise R. Aberle, William C. Black et al. Radiology profile →
Breast-Cancer Tumor Size, Overdiagnosis, and Mammography Screening Effectiveness

2016 458 citations Philip C. Prorok, Barnett S. Kramer et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Barnett S. Kramer

Since Specialization

Citations

This map shows the geographic impact of Barnett S. Kramer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barnett S. Kramer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barnett S. Kramer more than expected).

Fields of papers citing papers by Barnett S. Kramer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Barnett S. Kramer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barnett S. Kramer. The network helps show where Barnett S. Kramer may publish in the future.

Co-authorship network of co-authors of Barnett S. Kramer

This figure shows the co-authorship network connecting the top 25 collaborators of Barnett S. Kramer. A scholar is included among the top collaborators of Barnett S. Kramer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Barnett S. Kramer. Barnett S. Kramer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	False premises, false promises: celebrity endorsement of non-evidence-based anticancer interventions on social media 2025 ·Health Promotion International ·(unknown), Ray Moynihan, Barnett S. Kramer, Brooke Nickel	1
2	Design considerations and challenges in the CHinA National CancEr Screening (CHANCES) trial and Tomosynthesis Mammographic Imaging Screening Trial (TMIST) 2025 ·JNCI Monographs ·Ping Hu, Jon A. Steingrimsson, Elodia B. Cole, Jean Cormack, Barbara K. Dunn, Constantine Gatsonis, (unknown), Ni Li, Etta D. Pisano, Jie He, Barnett S. Kramer	1
3	Cancer overdiagnosis: A challenge in the era of screening 2022 ·SHILAP Revista de lepidopterología ·Barbara K. Dunn, Steven Woloshin, (unknown), Barnett S. Kramer	21
4	Prostate Cancer Screening — A Perspective on the Current State of the Evidence 2017 ·New England Journal of Medicine ·Paul F. Pinsky, Philip C. Prorok, Barnett S. Kramer	84
5	Population-based screening for cancer: hope and hype 2016 ·Nature Reviews Clinical Oncology ·Yiwey Shieh, Martin Eklund, George F. Sawaya, William C. Black, Barnett S. Kramer, Laura J. Esserman	97
6	5‐α‐Reductase inhibitors for prostate cancer chemoprevention: an updated Cochrane systematic review 2010 ·British Journal of Urology ·Timothy J Wilt, Roderick MacDonald, Karen L. Hagerty, Paul Schellhammer, James Tacklind, Mark R. Somerfield, Barnett S. Kramer	29
7	The National Lung Screening Trial: Overview and Study Design breakdown → 2010 ·Radiology ·(unknown), Denise R. Aberle, (unknown), William C. Black, Timothy R. Church, Richard M. Fagerstrom, Barbara Galen, Ilana F. Gareen, Constantine Gatsonis, Jonathan Goldin, John K. Gohagan, Bruce J. Hillman, C. Carl Jaffe, Barnett S. Kramer, David A. Lynch, Pamela M. Marcus, Mitchell D. Schnall, Daniel C. Sullivan, Dorothy Sullivan	899
8	Clinical trial design and evidence-based outcomes in the study of liver diseases 2009 ·Journal of Hepatology ·Jennifer M. Croswell, Barnett S. Kramer	13
9	Repeat prostate biopsy in the Prostate, Lung, Colorectal and Ovarian cancer screening trial 2007 ·British Journal of Urology ·Paul F. Pinsky, E. David Crawford, Barnett S. Kramer, Gerald L. Andriole, Edward P. Gelmann, Robert L. Grubb, Robert T. Greenlee, John K. Gohagan	29
10	Prostate‐specific antigen velocity and prostate cancer gleason grade and stage 2007 ·Cancer ·Paul F. Pinsky, Gerald L. Andriole, E. David Crawford, David Chia, Barnett S. Kramer, Robert L. Grubb, Robert T. Greenlee, John K. Gohagan	44
11	Identifying genes that contribute most to good classification in microarrays 2006 ·BMC Bioinformatics ·Stuart G. Baker, Barnett S. Kramer	45
12	Development Tracks for Cancer Prevention Markers 2004 ·Disease Markers ·Stuart G. Baker, Barnett S. Kramer, Philip C. Prorok	8
13	The fallacy of enrolling only high-risk subjects in cancer prevention trials: Is there a "free lunch"? 2004 ·BMC Medical Research Methodology ·Stuart G. Baker, Barnett S. Kramer, Donald K. Corle	5
14	Estimating the Cumulative Risk of a False‐Positive Test in a Repeated Screening Program 2004 ·Biometrics ·(unknown), Richard M. Fagerstrom, Philip C. Prorok, Barnett S. Kramer	21
15	The Lung Screening Study: The National Cancer Institute's Randomized Feasibility Study of Spiral CT versus Chest X-ray in Lung Cancer Screenin 2003 ·CHEST Journal ·Paul A. Kvale, John K. Gohagan, Pamela M. Marcus, Richard M. Fagerstrom, Paul F. Pinsky, Barnett S. Kramer, Philip C. Prorok	3
16	Estimating the cumulative risk of false positive cancer screenings 2003 ·BMC Medical Research Methodology ·Stuart G. Baker, (unknown), Barnett S. Kramer	21
17	General Keynote: Cancer Screening: Translation of Principles into Practice 2003 ·Gynecologic Oncology ·Barnett S. Kramer	5
18	Is screening for prostate cancer the current gold standard?--"no". 1997 ·PubMed ·Barnett S. Kramer, (unknown), (unknown)	12
19	A pilot study of interferon alfa-2a in combination with fluorouracil plus high-dose leucovorin in metastatic gastrointestinal carcinoma. 1991 ·Journal of Clinical Oncology ·Jean L. Grem, Nanette McAtee, Robert F. Murphy, Frank M. Balis, Seth M. Steinberg, J. Michael Hamilton, John M. Sorensen, Oliver Sartor, Barnett S. Kramer, Lori J. Goldstein	93
20	Randomized Phase II Evaluation of Iproplatin (CHIP) and Carboplatin (CBDCA) in Lung Cancer 1988 ·American Journal of Clinical Oncology ·Barnett S. Kramer, Robert Birch, (unknown), (unknown), Paolo De Simone, George Omura	18

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact